Published in Blood on January 16, 2013
Immunotherapy converts nonimmunogenic pancreatic tumors into immunogenic foci of immune regulation. Cancer Immunol Res (2014) 1.62
Cyclic GMP-AMP displays mucosal adjuvant activity in mice. PLoS One (2014) 1.44
First Demonstration of Antigen Induced Cytokine Expression by CD4-1+ Lymphocytes in a Poikilotherm: Studies in Zebrafish (Danio rerio). PLoS One (2015) 1.44
Doxorubicin eliminates myeloid-derived suppressor cells and enhances the efficacy of adoptive T-cell transfer in breast cancer. Cancer Res (2013) 1.42
Estradiol Enhances CD4+ T-Cell Anti-Viral Immunity by Priming Vaginal DCs to Induce Th17 Responses via an IL-1-Dependent Pathway. PLoS Pathog (2016) 1.41
IL-12 and IL-23 cytokines: from discovery to targeted therapies for immune-mediated inflammatory diseases. Nat Med (2015) 1.32
The Th17/Treg ratio, IL-1RA and sCD14 levels in primary HIV infection predict the T-cell activation set point in the absence of systemic microbial translocation. PLoS Pathog (2013) 1.24
Th17-mediated inflammation in asthma. Curr Opin Immunol (2013) 1.23
Interleukin-17 in human inflammatory diseases. Postepy Dermatol Alergol (2014) 1.21
ICOS-based chimeric antigen receptors program bipolar TH17/TH1 cells. Blood (2014) 1.11
Heterogeneous expression pattern of interleukin 17A (IL-17A), IL-17F and their receptors in synovium of rheumatoid arthritis, psoriatic arthritis and osteoarthritis: possible explanation for nonresponse to anti-IL-17 therapy? Arthritis Res Ther (2014) 0.97
HGK/MAP4K4 deficiency induces TRAF2 stabilization and Th17 differentiation leading to insulin resistance. Nat Commun (2014) 0.97
Ebola: translational science considerations. J Transl Med (2015) 0.96
The immunogenetics of Psoriasis: A comprehensive review. J Autoimmun (2015) 0.95
Heme oxygenase-1 exerts a protective role in ovalbumin-induced neutrophilic airway inflammation by inhibiting Th17 cell-mediated immune response. J Biol Chem (2013) 0.94
Basic biology and role of interleukin-17 in immunity and inflammation. Periodontol 2000 (2015) 0.92
Dengue virus infection: current concepts in immune mechanisms and lessons from murine models. Immunology (2014) 0.92
The role of the immune system in non-small cell lung carcinoma and potential for therapeutic intervention. Transl Lung Cancer Res (2015) 0.91
Epigenetic modulation of the immune function: a potential target for tolerance. Epigenetics (2013) 0.90
Development of a unique epigenetic signature during in vivo Th17 differentiation. Nucleic Acids Res (2015) 0.88
Th1/17 Polarization of CD4 T Cells Supports HIV-1 Persistence during Antiretroviral Therapy. J Virol (2015) 0.87
Th17 Cells Coordinate with Th22 Cells in Maintaining Homeostasis of Intestinal Tissues and both are Depleted in SIV-Infected Macaques. J AIDS Clin Res (2014) 0.87
Mechanisms of immune response regulation in lung cancer. Transl Lung Cancer Res (2014) 0.86
Diversity of HIV-1 reservoirs in CD4+ T-cell subpopulations. Curr Opin HIV AIDS (2016) 0.86
Transfer of myelin-reactive th17 cells impairs endogenous remyelination in the central nervous system of cuprizone-fed mice. J Neurosci (2015) 0.86
The multifaceted role of Th17 lymphocytes and their associated cytokines in cancer. Clin Dev Immunol (2013) 0.85
Staphylococcal enterotoxin A (SEA) stimulates STAT3 activation and IL-17 expression in cutaneous T-cell lymphoma. Blood (2016) 0.85
Identification of novel HIV-1 dependency factors in primary CCR4(+)CCR6(+)Th17 cells via a genome-wide transcriptional approach. Retrovirology (2015) 0.85
Th17 pathway-mediated immunopathogenesis of schizophrenia: mechanisms and implications. Schizophr Bull (2014) 0.84
Interleukin-12 enhances the function and anti-tumor activity in murine and human CD8(+) T cells. Cancer Immunol Immunother (2015) 0.84
Anti-CD20 therapy induces a memory Th1 response through the IFN-γ/IL-12 axis and prevents protumor regulatory T-cell expansion in mice. Leukemia (2014) 0.83
An animated landscape representation of CD4+ T-cell differentiation, variability, and plasticity: insights into the behavior of populations versus cells. Eur J Immunol (2014) 0.83
Antifungal Th Immunity: Growing up in Family. Front Immunol (2014) 0.83
Viral immune evasion in dengue: toward evidence-based revisions of clinical practice guidelines. Bioinformation (2014) 0.82
Unique macrophages different from M1/M2 macrophages inhibit T cell mitogenesis while upregulating Th17 polarization. Sci Rep (2014) 0.82
Human papillomavirus infection correlates with inflammatory Stat3 signaling activity and IL-17 level in patients with colorectal cancer. PLoS One (2015) 0.82
Lymphocyte roles in metabolic dysfunction: of men and mice. Trends Endocrinol Metab (2015) 0.81
New roles for CD14 and IL-β linking inflammatory dendritic cells to IL-17 production in memory CD4(+) T cells. Immunol Cell Biol (2016) 0.81
Th17 cells demonstrate stable cytokine production in a proallergic environment. J Immunol (2014) 0.80
Skewed Helper T-Cell Responses to IL-12 Family Cytokines Produced by Antigen-Presenting Cells and the Genetic Background in Behcet's Disease. Genet Res Int (2013) 0.80
The inducible costimulator augments Tc17 cell responses to self and tumor tissue. J Immunol (2015) 0.80
Arid5a regulates naive CD4+ T cell fate through selective stabilization of Stat3 mRNA. J Exp Med (2016) 0.80
T Helper Lymphocyte Subsets and Plasticity in Autoimmunity and Cancer: An Overview. Biomed Res Int (2015) 0.80
New insights into the heterogeneity of Th17 subsets contributing to HIV-1 persistence during antiretroviral therapy. Retrovirology (2016) 0.80
A Minimal Regulatory Network of Extrinsic and Intrinsic Factors Recovers Observed Patterns of CD4+ T Cell Differentiation and Plasticity. PLoS Comput Biol (2015) 0.80
Effects of Systemically Administered Hydrocortisone on the Human Immunome. Sci Rep (2016) 0.79
TGF-β signaling initiated in dendritic cells instructs suppressive effects on Th17 differentiation at the site of neuroinflammation. PLoS One (2014) 0.79
GIMAP5 Deficiency Is Associated with Increased AKT Activity in T Lymphocytes. PLoS One (2015) 0.79
iNKT and MAIT Cell Alterations in Diabetes. Front Immunol (2015) 0.79
Viral immune surveillance: Toward a TH17/TH9 gate to the central nervous system. Bioinformation (2015) 0.79
Antigen signal strength during priming determines effector CD4 T cell function and antigen sensitivity during influenza virus challenge. J Immunol (2014) 0.79
Protein kinase C θ regulates the phenotype of murine CD4+ Th17 cells. PLoS One (2014) 0.79
Induced Treg Cells Augment the Th17-Mediated Intestinal Inflammatory Response in a CTLA4-Dependent Manner. PLoS One (2016) 0.78
miR-27a and miR-214 exert opposite regulatory roles in Th17 differentiation via mediating different signaling pathways in peripheral blood CD4(+) T lymphocytes of patients with relapsing-remitting multiple sclerosis. Immunogenetics (2015) 0.78
T Cell Transcription Factors and Their Impact on HIV Expression. Virology (Auckl) (2013) 0.78
IL-15-dependent balance between Foxp3 and RORγt expression impacts inflammatory bowel disease. Nat Commun (2016) 0.78
Localization of CD8 T cell epitope within cardiac myosin heavy chain-α334-352 that induces autoimmune myocarditis in A/J mice. Int J Cardiol (2015) 0.78
Anti-N-methyl-D-aspartate receptor encephalitis: the clinical course in light of the chemokine and cytokine levels in cerebrospinal fluid. J Neuroinflammation (2016) 0.78
Increased Th17 cells and IL-17A exist in patients with B cell acute lymphoblastic leukemia and promote proliferation and resistance to daunorubicin through activation of Akt signaling. J Transl Med (2016) 0.78
STAT-5 is activated constitutively in T cells, B cells and monocytes from patients with primary Sjögren's syndrome. Clin Exp Immunol (2015) 0.78
Chronic graft-versus-host disease: biological insights from pre-clinical and clinical studies. Blood (2016) 0.78
Along the Axis between Type 1 and Type 2 Immunity; Principles Conserved in Evolution from Fish to Mammals. Biology (Basel) (2015) 0.77
A gradient of glucocorticoid sensitivity among helper T cell cytokines. Cytokine Growth Factor Rev (2016) 0.76
Human papillomavirus infection correlates with inflammatory Stat3 signaling activity and IL-17 expression in patients with breast cancer. Am J Transl Res (2016) 0.76
Digoxin Inhibits Induction of Experimental Autoimmune Uveitis in Mice, but Causes Severe Retinal Degeneration. Invest Ophthalmol Vis Sci (2016) 0.76
Dendritic Cells Regulate Treg-Th17 Axis in Obstructive Phase of Bile Duct Injury in Murine Biliary Atresia. PLoS One (2015) 0.76
Impaired T cell responsiveness to interleukin-6 in hematological patients with invasive aspergillosis. PLoS One (2015) 0.76
Pegylated Interferon α-2a Triggers NK-Cell Functionality and Specific T-Cell Responses in Patients with Chronic HBV Infection without HBsAg Seroconversion. PLoS One (2016) 0.76
IL-17/IL-10 double-producing T cells: new link between infections, immunosuppression and acute myeloid leukemia. J Transl Med (2015) 0.76
Transcriptional network profile on synovial fluid T cells in psoriatic arthritis. Clin Rheumatol (2015) 0.76
Suppressive IL-17A(+)Foxp3(+) and ex-Th17 IL-17A(neg)Foxp3(+) Treg cells are a source of tumour-associated Treg cells. Nat Commun (2017) 0.75
Regulation of pulmonary graft-versus-host disease by IL-26+CD26+CD4 T lymphocytes. J Immunol (2015) 0.75
IL-17A-producing T cells are associated with the progression of lung adenocarcinoma. Oncol Rep (2016) 0.75
HIV persists in CCR6+CD4+ T cells from colon and blood during antiretroviral therapy. AIDS (2017) 0.75
Comparative analysis of human and mouse transcriptomes of Th17 cell priming. Oncotarget (2016) 0.75
Serum Cytokine Profiles in Children with Crohn's Disease. Mediators Inflamm (2016) 0.75
Inherent low Erk and p38 activity reduce Fas Ligand expression and degranulation in T helper 17 cells leading to activation induced cell death resistance. Oncotarget (2016) 0.75
Interleukin-17 and type 17 helper T cells in cancer management and research. Immunotargets Ther (2014) 0.75
Surface-bound bovine serum albumin carrier protein as present in recombinant cytokine preparations amplifies T helper 17 cell polarization. Sci Rep (2016) 0.75
Th17 cytokine differentiation and loss of plasticity after SOCS1 inactivation in a cutaneous T-cell lymphoma. Oncotarget (2016) 0.75
Heterologous Vaccination and Checkpoint Blockade Synergize To Induce Antileukemia Immunity. J Immunol (2016) 0.75
Sm-p80-based schistosomiasis vaccine mediated epistatic interactions identified potential immune signatures for vaccine efficacy in mice and baboons. PLoS One (2017) 0.75
Increased Th17 cells in flow cytometer-sorted CD45RO-positive memory CD4 T cells from patients with systemic lupus erythematosus. Lupus Sci Med (2014) 0.75
Yin and yang of interleukin-17 in host immunity to infection. F1000Res (2017) 0.75
Cathepsin S Is Involved in Th17 Differentiation Through the Upregulation of IL-6 by Activating PAR-2 after Systemic Exposure to Lipopolysaccharide from Porphyromonas gingivalis. Front Pharmacol (2017) 0.75
Identification of IL-27/IL-27RA as a critical immune axis for in vivo HIV control. J Virol (2017) 0.75
Increased Levels of Serum Interleukin-17 in Patients with Hashimoto's Thyroiditis. Indian J Endocrinol Metab (2017) 0.75
IL-17 Promotes Differentiation of Splenic LSK(-) Lymphoid Progenitors into B Cells following Plasmodium yoelii Infection. J Immunol (2017) 0.75
Clonal expansion of genome-intact HIV-1 in functionally polarized Th1 CD4+ T cells. J Clin Invest (2017) 0.75
Control of regulatory T cell development by the transcription factor Foxp3. Science (2003) 40.32
Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins. J Immunol (1986) 35.41
The orphan nuclear receptor RORgammat directs the differentiation program of proinflammatory IL-17+ T helper cells. Cell (2006) 33.94
TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties. Annu Rev Immunol (1989) 31.72
Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat Immunol (2005) 30.22
TGFbeta in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells. Immunity (2006) 29.29
IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J Exp Med (2005) 28.73
Immunity, inflammation, and cancer. Cell (2010) 28.27
A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17. Nat Immunol (2005) 27.17
Transforming growth factor-beta induces development of the T(H)17 lineage. Nature (2006) 25.91
IL-17 and Th17 Cells. Annu Rev Immunol (2009) 23.02
Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain. Nature (2003) 22.89
Induction of intestinal Th17 cells by segmented filamentous bacteria. Cell (2009) 20.29
A novel transcription factor, T-bet, directs Th1 lineage commitment. Cell (2000) 17.61
IL-21 initiates an alternative pathway to induce proinflammatory T(H)17 cells. Nature (2007) 16.59
IL-6 programs T(H)-17 cell differentiation by promoting sequential engagement of the IL-21 and IL-23 pathways. Nat Immunol (2007) 16.21
Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12. Immunity (2000) 16.03
Divergent pro- and antiinflammatory roles for IL-23 and IL-12 in joint autoimmune inflammation. J Exp Med (2003) 14.60
Immunological and inflammatory functions of the interleukin-1 family. Annu Rev Immunol (2009) 14.33
TGF-beta-induced Foxp3 inhibits T(H)17 cell differentiation by antagonizing RORgammat function. Nature (2008) 14.26
Interleukin (IL)-22 and IL-17 are coexpressed by Th17 cells and cooperatively enhance expression of antimicrobial peptides. J Exp Med (2006) 13.74
T helper 17 lineage differentiation is programmed by orphan nuclear receptors ROR alpha and ROR gamma. Immunity (2007) 13.29
Reciprocal TH17 and regulatory T cell differentiation mediated by retinoic acid. Science (2007) 12.79
Surface phenotype and antigenic specificity of human interleukin 17-producing T helper memory cells. Nat Immunol (2007) 12.72
The transcription factor GATA-3 is necessary and sufficient for Th2 cytokine gene expression in CD4 T cells. Cell (1997) 12.68
Interleukin-2 signaling via STAT5 constrains T helper 17 cell generation. Immunity (2007) 12.12
Predominant TH2-like bronchoalveolar T-lymphocyte population in atopic asthma. N Engl J Med (1992) 11.90
Reciprocal expression of interferon gamma or interleukin 4 during the resolution or progression of murine leishmaniasis. Evidence for expansion of distinct helper T cell subsets. J Exp Med (1989) 11.36
Phenotypic and functional features of human Th17 cells. J Exp Med (2007) 11.33
TGF-beta and IL-6 drive the production of IL-17 and IL-10 by T cells and restrain T(H)-17 cell-mediated pathology. Nat Immunol (2007) 11.14
IL-23 and IL-17 in the establishment of protective pulmonary CD4+ T cell responses after vaccination and during Mycobacterium tuberculosis challenge. Nat Immunol (2007) 10.71
The biological functions of T helper 17 cell effector cytokines in inflammation. Immunity (2008) 10.55
STAT3 regulates cytokine-mediated generation of inflammatory helper T cells. J Biol Chem (2007) 10.41
The aryl hydrocarbon receptor links TH17-cell-mediated autoimmunity to environmental toxins. Nature (2008) 10.15
Global mapping of H3K4me3 and H3K27me3 reveals specificity and plasticity in lineage fate determination of differentiating CD4+ T cells. Immunity (2009) 9.73
Defective CD8 T cell memory following acute infection without CD4 T cell help. Science (2003) 9.67
A large-scale genetic association study confirms IL12B and leads to the identification of IL23R as psoriasis-risk genes. Am J Hum Genet (2006) 9.56
IL-22 mediates mucosal host defense against Gram-negative bacterial pneumonia. Nat Med (2008) 9.05
Syk- and CARD9-dependent coupling of innate immunity to the induction of T helper cells that produce interleukin 17. Nat Immunol (2007) 8.92
Gut-residing segmented filamentous bacteria drive autoimmune arthritis via T helper 17 cells. Immunity (2010) 8.90
Late developmental plasticity in the T helper 17 lineage. Immunity (2009) 8.81
T cell interleukin-17 induces stromal cells to produce proinflammatory and hematopoietic cytokines. J Exp Med (1996) 8.59
Impaired T(H)17 cell differentiation in subjects with autosomal dominant hyper-IgE syndrome. Nature (2008) 8.17
Stat6 is required for mediating responses to IL-4 and for development of Th2 cells. Immunity (1996) 8.16
Generation of pathogenic T(H)17 cells in the absence of TGF-β signalling. Nature (2010) 7.50
A human memory T cell subset with stem cell-like properties. Nat Med (2011) 7.47
T-bet is a STAT1-induced regulator of IL-12R expression in naïve CD4+ T cells. Nat Immunol (2002) 7.28
CD4 T cells: fates, functions, and faults. Blood (2008) 7.03
Acquisition of full effector function in vitro paradoxically impairs the in vivo antitumor efficacy of adoptively transferred CD8+ T cells. J Clin Invest (2005) 7.01
RORγt drives production of the cytokine GM-CSF in helper T cells, which is essential for the effector phase of autoimmune neuroinflammation. Nat Immunol (2011) 6.96
Critical regulation of early Th17 cell differentiation by interleukin-1 signaling. Immunity (2009) 6.87
Tumor-specific Th17-polarized cells eradicate large established melanoma. Blood (2008) 6.81
The interleukin 23 receptor is essential for the terminal differentiation of interleukin 17-producing effector T helper cells in vivo. Nat Immunol (2009) 6.74
Inhibiting Stat3 signaling in the hematopoietic system elicits multicomponent antitumor immunity. Nat Med (2005) 6.58
Innate lymphoid cells drive interleukin-23-dependent innate intestinal pathology. Nature (2010) 6.44
Structure and signalling in the IL-17 receptor family. Nat Rev Immunol (2009) 6.38
IL-23 promotes tumour incidence and growth. Nature (2006) 6.30
Lack of IL-4-induced Th2 response and IgE class switching in mice with disrupted Stat6 gene. Nature (1996) 6.17
IL-22 ameliorates intestinal inflammation in a mouse model of ulcerative colitis. J Clin Invest (2008) 6.17
Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis. N Engl J Med (2012) 6.17
HIF1alpha-dependent glycolytic pathway orchestrates a metabolic checkpoint for the differentiation of TH17 and Treg cells. J Exp Med (2011) 5.99
Fate mapping of IL-17-producing T cells in inflammatory responses. Nat Immunol (2011) 5.98
The development of inflammatory T(H)-17 cells requires interferon-regulatory factor 4. Nat Immunol (2007) 5.83
Inhibition of Th1 development mediated by GATA-3 through an IL-4-independent mechanism. Immunity (1998) 5.75
Wnt signaling arrests effector T cell differentiation and generates CD8+ memory stem cells. Nat Med (2009) 5.54
The encephalitogenicity of T(H)17 cells is dependent on IL-1- and IL-23-induced production of the cytokine GM-CSF. Nat Immunol (2011) 5.41
A protective function for interleukin 17A in T cell-mediated intestinal inflammation. Nat Immunol (2009) 5.26
Either a Th17 or a Th1 effector response can drive autoimmunity: conditions of disease induction affect dominant effector category. J Exp Med (2008) 5.25
Stat3 and Stat4 direct development of IL-17-secreting Th cells. J Immunol (2007) 5.16
IL-17 can promote tumor growth through an IL-6-Stat3 signaling pathway. J Exp Med (2009) 5.05
Downregulation of Th1 cytokine production accompanies induction of Th2 responses by a parasitic helminth, Schistosoma mansoni. J Exp Med (1991) 5.04
Helping the CD8(+) T-cell response. Nat Rev Immunol (2004) 4.90
Interleukin-21: basic biology and implications for cancer and autoimmunity. Annu Rev Immunol (2008) 4.90
A validated regulatory network for Th17 cell specification. Cell (2012) 4.82
Phenotype, distribution, generation, and functional and clinical relevance of Th17 cells in the human tumor environments. Blood (2009) 4.80
Production of interleukin 22 but not interleukin 17 by a subset of human skin-homing memory T cells. Nat Immunol (2009) 4.69
T helper 17 cells promote cytotoxic T cell activation in tumor immunity. Immunity (2009) 4.69
Innate and adaptive interleukin-22 protects mice from inflammatory bowel disease. Immunity (2008) 4.67
CD8+ T-cell memory in tumor immunology and immunotherapy. Immunol Rev (2006) 4.49
Induction and molecular signature of pathogenic TH17 cells. Nat Immunol (2012) 4.43
IL-12- and IL-23-modulated T cells induce distinct types of EAE based on histology, CNS chemokine profile, and response to cytokine inhibition. J Exp Med (2008) 4.38
Differential Th17 CD4 T-cell depletion in pathogenic and nonpathogenic lentiviral infections. Blood (2008) 4.34
Human interleukin 17-producing cells originate from a CD161+CD4+ T cell precursor. J Exp Med (2008) 4.30
Th17 cells in human disease. Immunol Rev (2008) 4.27
Suppression of TH17 differentiation and autoimmunity by a synthetic ROR ligand. Nature (2011) 4.19
Endogenous IL-17 contributes to reduced tumor growth and metastasis. Blood (2009) 4.13
IL-22 is required for Th17 cell-mediated pathology in a mouse model of psoriasis-like skin inflammation. J Clin Invest (2008) 4.12
Th22 cells represent a distinct human T cell subset involved in epidermal immunity and remodeling. J Clin Invest (2009) 4.10
Experimental autoimmune encephalitis and inflammation in the absence of interleukin-12. J Clin Invest (2002) 4.04
The Th1/Th2 paradigm. Immunol Today (1997) 3.96
The IL-23/Th17 axis in the immunopathogenesis of psoriasis. J Invest Dermatol (2009) 3.93
Opposing regulation of the locus encoding IL-17 through direct, reciprocal actions of STAT3 and STAT5. Nat Immunol (2011) 3.91
Interactions among the transcription factors Runx1, RORgammat and Foxp3 regulate the differentiation of interleukin 17-producing T cells. Nat Immunol (2008) 3.88
Cutting edge: Th17 and regulatory T cell dynamics and the regulation by IL-2 in the tumor microenvironment. J Immunol (2007) 3.81
The AP-1 transcription factor Batf controls T(H)17 differentiation. Nature (2009) 3.75
T helper cell fate specified by kinase-mediated interaction of T-bet with GATA-3. Science (2005) 3.65
Prevention of experimental autoimmune encephalomyelitis by antibodies against interleukin 12. J Exp Med (1995) 3.65
Opposing signals from the Bcl6 transcription factor and the interleukin-2 receptor generate T helper 1 central and effector memory cells. Immunity (2011) 3.58
Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science (2002) 19.77
Cancer immunotherapy: moving beyond current vaccines. Nat Med (2004) 17.61
Cancer regression in patients after transfer of genetically engineered lymphocytes. Science (2006) 16.96
Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol (2005) 12.88
Tumor regression and autoimmunity after reversal of a functionally tolerant state of self-reactive CD8+ T cells. J Exp Med (2003) 11.08
Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc Natl Acad Sci U S A (2003) 10.71
Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. J Clin Oncol (2008) 10.13
Adoptive cell transfer: a clinical path to effective cancer immunotherapy. Nat Rev Cancer (2008) 9.82
Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4. J Clin Oncol (2005) 9.72
Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. Blood (2009) 9.24
Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. J Clin Oncol (2011) 9.19
Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clin Cancer Res (2011) 9.03
Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells. J Exp Med (2005) 8.13
Adoptive immunotherapy for cancer: building on success. Nat Rev Immunol (2006) 7.76
A human memory T cell subset with stem cell-like properties. Nat Med (2011) 7.47
Acquisition of full effector function in vitro paradoxically impairs the in vivo antitumor efficacy of adoptively transferred CD8+ T cells. J Clin Invest (2005) 7.01
CD8+ T cell immunity against a tumor/self-antigen is augmented by CD4+ T helper cells and hindered by naturally occurring T regulatory cells. J Immunol (2005) 6.95
Tumor-specific Th17-polarized cells eradicate large established melanoma. Blood (2008) 6.81
Natural selection of tumor variants in the generation of "tumor escape" phenotypes. Nat Immunol (2002) 5.75
Wnt signaling arrests effector T cell differentiation and generates CD8+ memory stem cells. Nat Med (2009) 5.54
Central memory self/tumor-reactive CD8+ T cells confer superior antitumor immunity compared with effector memory T cells. Proc Natl Acad Sci U S A (2005) 5.21
Tumor-reactive CD4(+) T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hosts. J Exp Med (2010) 4.90
Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy. J Immunother (2013) 4.80
IL-15 enhances the in vivo antitumor activity of tumor-reactive CD8+ T cells. Proc Natl Acad Sci U S A (2004) 4.70
T helper 17 cells promote cytotoxic T cell activation in tumor immunity. Immunity (2009) 4.69
Synergy of IL-21 and IL-15 in regulating CD8+ T cell expansion and function. J Exp Med (2005) 4.60
CD8+ T-cell memory in tumor immunology and immunotherapy. Immunol Rev (2006) 4.49
Phase I study of the intravenous administration of attenuated Salmonella typhimurium to patients with metastatic melanoma. J Clin Oncol (2002) 4.15
Tumor progression can occur despite the induction of very high levels of self/tumor antigen-specific CD8+ T cells in patients with melanoma. J Immunol (2005) 3.73
Microbial translocation augments the function of adoptively transferred self/tumor-specific CD8+ T cells via TLR4 signaling. J Clin Invest (2007) 3.54
IL-2 and IL-21 confer opposing differentiation programs to CD8+ T cells for adoptive immunotherapy. Blood (2008) 3.52
T(H)17 cells in tumour immunity and immunotherapy. Nat Rev Immunol (2010) 3.39
T cells targeting carcinoembryonic antigen can mediate regression of metastatic colorectal cancer but induce severe transient colitis. Mol Ther (2010) 3.29
Hematopoietic stem cells promote the expansion and function of adoptively transferred antitumor CD8 T cells. J Clin Invest (2007) 3.02
Increased intensity lymphodepletion and adoptive immunotherapy--how far can we go? Nat Clin Pract Oncol (2006) 2.97
Sinks, suppressors and antigen presenters: how lymphodepletion enhances T cell-mediated tumor immunotherapy. Trends Immunol (2005) 2.97
Naive tumor-specific CD4(+) T cells differentiated in vivo eradicate established melanoma. J Exp Med (2010) 2.91
Paths to stemness: building the ultimate antitumour T cell. Nat Rev Cancer (2012) 2.79
Th17 cells are long lived and retain a stem cell-like molecular signature. Immunity (2011) 2.64
Antiangiogenic agents can increase lymphocyte infiltration into tumor and enhance the effectiveness of adoptive immunotherapy of cancer. Cancer Res (2010) 2.57
Adoptively transferred effector cells derived from naive rather than central memory CD8+ T cells mediate superior antitumor immunity. Proc Natl Acad Sci U S A (2009) 2.56
Adoptive transfer of syngeneic T cells transduced with a chimeric antigen receptor that recognizes murine CD19 can eradicate lymphoma and normal B cells. Blood (2010) 2.52
Inhibiting glycolytic metabolism enhances CD8+ T cell memory and antitumor function. J Clin Invest (2013) 2.50
BACH2 represses effector programs to stabilize T(reg)-mediated immune homeostasis. Nature (2013) 2.36
Adoptive immunotherapy of cancer using CD4(+) T cells. Curr Opin Immunol (2009) 2.31
Increased intensity lymphodepletion enhances tumor treatment efficacy of adoptively transferred tumor-specific T cells. J Immunother (2010) 2.30
De novo induction of a cancer/testis antigen by 5-aza-2'-deoxycytidine augments adoptive immunotherapy in a murine tumor model. Cancer Res (2006) 2.27
Vaccine-stimulated, adoptively transferred CD8+ T cells traffic indiscriminately and ubiquitously while mediating specific tumor destruction. J Immunol (2004) 2.22
Prospective molecular profiling of melanoma metastases suggests classifiers of immune responsiveness. Cancer Res (2002) 2.21
Treatment of metastatic melanoma using interleukin-2 alone or in conjunction with vaccines. Clin Cancer Res (2008) 2.15
Tumor-specific CD8+ T cells expressing interleukin-12 eradicate established cancers in lymphodepleted hosts. Cancer Res (2010) 2.13
Immunization of patients with metastatic melanoma using both class I- and class II-restricted peptides from melanoma-associated antigens. J Immunother (2003) 2.10
Effective tumor treatment targeting a melanoma/melanocyte-associated antigen triggers severe ocular autoimmunity. Proc Natl Acad Sci U S A (2008) 2.07
Superior T memory stem cell persistence supports long-lived T cell memory. J Clin Invest (2013) 2.06
High-efficiency transfection of primary human and mouse T lymphocytes using RNA electroporation. Mol Ther (2005) 2.04
Type 17 CD8+ T cells display enhanced antitumor immunity. Blood (2009) 2.02
Human effector CD8+ T cells derived from naive rather than memory subsets possess superior traits for adoptive immunotherapy. Blood (2010) 2.01
Regulation of nucleosome landscape and transcription factor targeting at tissue-specific enhancers by BRG1. Genome Res (2011) 2.00
CD8+ enriched "young" tumor infiltrating lymphocytes can mediate regression of metastatic melanoma. Clin Cancer Res (2010) 1.92
IL-12 triggers a programmatic change in dysfunctional myeloid-derived cells within mouse tumors. J Clin Invest (2011) 1.90
Suppressors of cytokine signaling (SOCS) in T cell differentiation, maturation, and function. Trends Immunol (2009) 1.89
Alphavirus-based DNA vaccine breaks immunological tolerance by activating innate antiviral pathways. Nat Med (2002) 1.88
Therapeutic cancer vaccines: are we there yet? Immunol Rev (2011) 1.86
Determinants of successful CD8+ T-cell adoptive immunotherapy for large established tumors in mice. Clin Cancer Res (2011) 1.82
CD4+CD25+ T regulatory cells, immunotherapy of cancer, and interleukin-2. J Immunother (2005) 1.78
Ocular and systemic autoimmunity after successful tumor-infiltrating lymphocyte immunotherapy for recurrent, metastatic melanoma. Ophthalmology (2009) 1.78
Cellular constituents of immune escape within the tumor microenvironment. Cancer Res (2012) 1.75
Dendritic cells strongly boost the antitumor activity of adoptively transferred T cells in vivo. Cancer Res (2004) 1.74
Less is more: lymphodepletion followed by hematopoietic stem cell transplant augments adoptive T-cell-based anti-tumor immunotherapy. Curr Opin Immunol (2005) 1.74
Randomized selection design trial evaluating CD8+-enriched versus unselected tumor-infiltrating lymphocytes for adoptive cell therapy for patients with melanoma. J Clin Oncol (2013) 1.67
Identification, isolation and in vitro expansion of human and nonhuman primate T stem cell memory cells. Nat Protoc (2012) 1.63
The stoichiometric production of IL-2 and IFN-γ mRNA defines memory T cells that can self-renew after adoptive transfer in humans. Sci Transl Med (2012) 1.61
Toll-like receptors in tumor immunotherapy. Clin Cancer Res (2007) 1.60
Immunological and antitumor effects of IL-23 as a cancer vaccine adjuvant. J Immunol (2006) 1.59
Agonist anti-GITR antibody enhances vaccine-induced CD8(+) T-cell responses and tumor immunity. Cancer Res (2006) 1.57
Cell transfer therapy for cancer: lessons from sequential treatments of a patient with metastatic melanoma. J Immunother (2003) 1.55
Gene therapy using genetically modified lymphocytes targeting VEGFR-2 inhibits the growth of vascularized syngenic tumors in mice. J Clin Invest (2010) 1.53
Programming CD8+ T cells for effective immunotherapy. Curr Opin Immunol (2006) 1.51
MicroRNA-155 is required for effector CD8+ T cell responses to virus infection and cancer. Immunity (2013) 1.51
Repression of the DNA-binding inhibitor Id3 by Blimp-1 limits the formation of memory CD8+ T cells. Nat Immunol (2011) 1.51
Sorting through subsets: which T-cell populations mediate highly effective adoptive immunotherapy? J Immunother (2012) 1.47
Recombinant fowlpox viruses encoding the anchor-modified gp100 melanoma antigen can generate antitumor immune responses in patients with metastatic melanoma. Clin Cancer Res (2003) 1.46
Development of replication-defective lymphocytic choriomeningitis virus vectors for the induction of potent CD8+ T cell immunity. Nat Med (2010) 1.45
A TCR targeting the HLA-A*0201-restricted epitope of MAGE-A3 recognizes multiple epitopes of the MAGE-A antigen superfamily in several types of cancer. J Immunol (2010) 1.45
Interleukin-2-dependent mechanisms of tolerance and immunity in vivo. J Immunol (2006) 1.43
Wnt/beta-catenin signaling in T-cell immunity and cancer immunotherapy. Clin Cancer Res (2010) 1.40
Structures of MART-126/27-35 Peptide/HLA-A2 complexes reveal a remarkable disconnect between antigen structural homology and T cell recognition. J Mol Biol (2007) 1.36
Improving adoptive T cell therapy by targeting and controlling IL-12 expression to the tumor environment. Mol Ther (2011) 1.36
Interleukin-7-dependent expansion and persistence of melanoma-specific T cells in lymphodepleted mice lead to tumor regression and editing. Cancer Res (2005) 1.36
Reassessing target antigens for adoptive T-cell therapy. Nat Biotechnol (2013) 1.34
Immune evasion by murine melanoma mediated through CC chemokine receptor-10. J Exp Med (2003) 1.34
Pharmacologic induction of CD8+ T cell memory: better living through chemistry. Sci Transl Med (2009) 1.34
Local delivery of interleukin-12 using T cells targeting VEGF receptor-2 eradicates multiple vascularized tumors in mice. Clin Cancer Res (2012) 1.32
Poor immunogenicity of a self/tumor antigen derives from peptide-MHC-I instability and is independent of tolerance. J Clin Invest (2004) 1.30
Cancer vaccines: progress reveals new complexities. J Clin Invest (2002) 1.29
Inability to immunize patients with metastatic melanoma using plasmid DNA encoding the gp100 melanoma-melanocyte antigen. Hum Gene Ther (2003) 1.28
Immune targeting of fibroblast activation protein triggers recognition of multipotent bone marrow stromal cells and cachexia. J Exp Med (2013) 1.27
Increased immunogenicity of an anchor-modified tumor-associated antigen is due to the enhanced stability of the peptide/MHC complex: implications for vaccine design. J Immunol (2005) 1.27
Extrathymic generation of tumor-specific T cells from genetically engineered human hematopoietic stem cells via Notch signaling. Cancer Res (2007) 1.25